Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,813 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model.
Callegari E, D'Abundo L, Guerriero P, Simioni C, Elamin BK, Russo M, Cani A, Bassi C, Zagatti B, Giacomelli L, Blandamura S, Moshiri F, Ultimo S, Frassoldati A, Altavilla G, Gramantieri L, Neri LM, Sabbioni S, Negrini M. Callegari E, et al. Among authors: russo m. Mol Ther Nucleic Acids. 2018 Jun 1;11:485-493. doi: 10.1016/j.omtn.2018.04.002. Epub 2018 Apr 12. Mol Ther Nucleic Acids. 2018. PMID: 29858083 Free PMC article.
Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study.
Barbanti P, Aurilia C, Torelli P, Egeo G, d'Onofrio F, Finocchi C, Carnevale A, Viticchi G, Russo M, Quintana S, Orlando B, Fiorentini G, Messina R, Bartolini M, Pistoia F, Filippi M, Bonassi S, Cevoli S, Mannocci A; Italian Migraine Registry (I-GRAINE) study group. Barbanti P, et al. Among authors: russo m. J Neurol. 2025 Jan 25;272(2):170. doi: 10.1007/s00415-025-12911-w. J Neurol. 2025. PMID: 39862304
Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD, Mueller S, Filbin MG, Grill J, Hawkins C, Jones C, Donoghue M, Drezner N, Weiner S, Russo M, Dun MD, Allen JE, Alonso M, Benaim E, Buenger V, de Rojas T, Desserich K, Fox E, Friend J, Glade Bender J, Hargrave D, Jensen M, Kholmanskikh O, Kieran MW, Knoderer H, Koschmann C, Lesa G, Ligas F, Lipsman N, Ludwinski D, Marshall L, McDonough J, McNicholl AG, Mirsky D, Monje M, Nysom K, Pappo A, Rosenfield A, Scobie N, Slaughter J, Smith M, Souweidane M, Straathof K, Ward L, Weigel B, Zamoryakhin D, Karres D, Vassal G. Pearson AD, et al. Among authors: russo m. Eur J Cancer. 2025 Jan 13;217:115230. doi: 10.1016/j.ejca.2025.115230. Online ahead of print. Eur J Cancer. 2025. PMID: 39854822 Review.
Medullary thyroid cancer in MEN2 pediatric/adolescent carriers of RET mutation: genotype/phenotype correlation and outcome in a retrospective series of 23 patients.
Di Benedetto G, Barca I, De Gregorio L, Scollo C, Gianì F, Martorana F, Russo M, Frasca F, Pellegriti G, Sapuppo G. Di Benedetto G, et al. Among authors: russo m. Front Oncol. 2025 Jan 7;14:1464890. doi: 10.3389/fonc.2024.1464890. eCollection 2024. Front Oncol. 2025. PMID: 39839784 Free PMC article.
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension.
Adams D, Wixner J, Polydefkis M, Berk JL, Conceição IM, Dispenzieri A, Peltier A, Ueda M, Bender S, Capocelli K, Jay PY, Yureneva E, Obici L; patisiran Global OLE study group. Adams D, et al. JAMA Neurol. 2025 Jan 13. doi: 10.1001/jamaneurol.2024.4631. Online ahead of print. JAMA Neurol. 2025. PMID: 39804640
3,813 results